All In Biotech

Drug Trial Radar · NCT04917302

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 13, 2020

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
China Medical University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Science and Technology, Taiwan
First posted
Jun 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.

Conditions

  • Schizophrenia

Interventions

  • NMDAE plus AIFADrug

    Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.

  • NMDAE plus Placebo CapDrug

    Use of an NMDA enhancer plus placebo as a comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Positive and Negative Syndrome Scale (PANSS)Time frame: week 0, 2, 4, 6, 9, 12]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Psychiatry, China Medical University Hospital

    Taichung, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.